Skip to main content
SpringerLink
Log in

Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

A Letter to the editor to this article was published on 01 September 2023

The Original Article was published on 10 July 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Price MZ, Price RL. Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder. CNS Drugs. 2023;37:655–60. https://doi.org/10.1007/s40263-023-01023-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Clemow DB, Bushe CJ. Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. J Psychopharmacol. 2015;29(12):1221–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

    Uday Pande, Nitin R. Gaikwad & Alok Singh

Authors
  1. Uday Pande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nitin R. Gaikwad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alok Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alok Singh.

Ethics declarations

Funding

No funding was received for the publication of this letter.

Conflict of interest

The authors have no conflicts of interest to declare.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author contributions

All authors contributed equally.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pande, U., Gaikwad, N.R. & Singh, A. Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”. CNS Drugs 37, 937–938 (2023). https://doi.org/10.1007/s40263-023-01034-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-023-01034-3

Search

Navigation